Healthcare entity
Of the tracked stories, 1 of 2 also mention Andrew Berens, the most common co-covered peer. Source depth averages 1.5 original sources per story, versus 5.3 across the same-window beat baseline. Across a 120-day span, the pace is roughly 0.1 stories per week.
Last mentioned: Aug 1, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 1 of 2 also mention Andrew Berens, the most common co-covered peer. Source depth averages 1.5 original sources per story, versus 5.3 across the same-window beat baseline. Across a 120-day span, the pace is roughly 0.1 stories per week. At 5, the average consequence score sits below the same-window beat average of 6.4. The clearest coverage concentration is medical-devices: 1 of 2 stories, with the rest divided among 1 other category. We currently track 2 Healthcare stories that mention Pomerantz LLP, published between March 23, 2026 and July 20, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 263 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Pomerantz LLP. Shared-story counts are live from our verified record — not editorial picks.
Litigation Notice
Pomerantz LLP issues first public alert regarding the class action filing against Boston Scientific.
Form 8-K Filing
BSX files notice with the SEC regarding 'Other Events' involving executive shifts and operational updates.
Q4 2025 Earnings
Company reports financial results and provides updated guidance on clinical timelines.
AVANT GUARD Trial Pause
Boston Scientific announces a pause in its FARAPULSE PFA trial, citing the need for data review.
Pomerantz LLP probes Celcuity after FDA-approved breast cancer therapy Revtorpyk sees delayed Q3 2026 commercial launch, sending shares down 17.6%. Analysts question prior launch readiness; health investors weigh biotech regulatory and execution risks.
Source: prnewswire.com
Pomerantz LLP has initiated a class action investigation and filing against Boston Scientific Corporation (BSX), alleging the medical device giant made misleading statements regarding its clinical trials and business prospects. The litigation follows a period of heightened volatility for the company's cardiovascular portfolio, specifically concerning the FARAPULSE PFA system and recent trial adjustments.
Pomerantz LLP is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
